Amidst the deluge of stuff I think peaceAAKI has made one of the most pertinent points that many should digest fully...
"Mathew Lehman with 10 years heading a CRO through numerous drugs development was the logical move to take the top seat - if you want the best hands in drug development that's where you get it. Who do you think big pharma outsource most of their work to ?"
Diverting funds to where results for shareholders are most likely seems a fundamentally sound move by someone appointed to direct PRR on the world-stage. Listing in Frankfurt should not be undervalued as well if one seeks institutional and/or private investors from within the top economies.
I sold at 20 and am looking at PRR very closely.
Amidst the deluge of stuff I think peaceAAKI has made one of the...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
-0.010(3.51%) |
Mkt cap ! $400.0M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.3¢ | 27.0¢ | $1.034M | 3.758M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 98156 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 85523 | 9 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |